A recently published study suggests that sirolimus is an attractive treatment option for the prevention of secondary skin cancer in kidney transplant recipients. However, before we think about switching all patients with a previous skin cancer (or with any other malignancy) to sirolimus, we should have a closer look at the data.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ulrich, C., Kanitakis, J., Stockfleth, E. & Euvrard, S. Skin cancer in organ transplant recipients—where do we stand today? Am. J. Transplant. 8, 2192–2198 (2008).
Halleck, F. et al. An evaluation of sirolimus in renal transplantation. Expert Opin. Drug Metab. Toxicol. http://dx.doi.org/10.1517/17425255.2012.719874.
Campbell, S. B., Walker, R., Tai, S. S., Jiang, Q. & Russ, G. R. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am. J. Transplant. 12, 1146–1156 (2012).
de Fijter, J. W. et al. Reduced cutaneous squamous cell carcinoma after conversion to sirolimus: a 2-year prospective open-label multicenter trial [abstract #450]. Presented at the American Transplant Congress 2012.
Mathew, T., Kreis, H. & Friend, P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin. Transplant. 18, 446–449 (2004).
Salgo, R. et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am. J. Transplant. 10, 1385–1393 (2010).
Euvrard, S. et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N. Engl. J. Med. 367, 329–339 (2012).
Campistol, J. M. et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J. Am. Soc. Nephrol. 17, 581–589 (2006).
Alberú, J. et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 92, 303–310 (2011).
Cravedi, P., Ruggenenti, P. & Remuzzi, G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int. 78, 1068–1074 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Klemens Budde has received research grants and/or honoraria from AiCuris, Astellas, Bristol-Myers Squibb, Hexal, Novartis Pharma, Pfizer, Roche, Siemens, TCL Pharma und Veloxis Pharma.
Fabian Halleck declares no competing interests.
Supplementary information
Supplementary Table 1
Prospective RCTs investigating the effect of conversion to sirolimus in patients with skin tumours (DOC 45 kb)
Rights and permissions
About this article
Cite this article
Halleck, F., Budde, K. Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol 8, 687–689 (2012). https://doi.org/10.1038/nrneph.2012.216
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.216
This article is cited by
-
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Nature Reviews Nephrology (2016)
-
Hauttumoren nach Organtransplantation
Der Nephrologe (2013)
